News und Analysen
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate
Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the second quarter ended April 30, 2023, an increase of 6.8% compared to the second quarter of 2022 and up 9.5% on a
Agilent to Present at Jefferies and Goldman Sachs Healthcare Conferences
Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session.
Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents
Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support
Agilent Announces Cash Dividend of 22.5 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on July 26, 2023, to all shareholders of record as of the close of
Pfizer Prices $31,000,000,000 Debt Offering
Pfizer Inc. (NYSE:PFE) (“Pfizer”) today announced the pricing of a debt offering consisting of eight tranches of notes (collectively, the “Notes”):
$3,000,000,000 aggregate principal amount of
Agilent Wins SEAL Award for Innovative Products that Help Customers Achieve Their Sustainability Goals
Agilent Technologies Inc. (NYSE: A) today received a SEAL Business Sustainability Award for producing products and technology that are helping analytical and clinical labs reduce their carbon
Pfizer Announces Proposed Notes Offering
Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd. (the “Issuer”), has commenced a multi-series offering of senior
Humana to Partner with Two National Durable Medical Equipment Organizations
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that it has reached agreement with two national organizations to provide Durable Medical Equipment (DME) services to
Humana and Longevity Health Partner to Expand Access to Special Needs Plans for Medicare Beneficiaries
Longevity Health Plan and Humana Inc. (NYSE: HUM) today announced a new partnership to expand special needs health plan offerings that support the unique requirements of Medicare-eligible
Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye
Agilent Technologies Inc. (NYSE: A) announced today that Dr. Jiangbin Ye has received an Agilent Solutions Innovation Research Award (SIRA). The award supports drug discovery and development
Agilent to Announce Second-Quarter Fiscal Year 2023 Financial Results May 23
Agilent Technologies Inc. (NYSE: A) will release financial results and hold an earnings conference call for the second quarter of fiscal year 2023 after the stock market closes on Tuesday, May 23
Pfizer Declares Second-Quarter 2023 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company’s common stock, payable June 9, 2023, to holders of the Common Stock
Pfizer Reports First-Quarter 2023 Results
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2023 and reaffirmed full-year 2023 financial guidance.
The first-quarter 2023 earnings presentation and accompanying
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive
Agilent Presents 2023 Darlene Solomon Award to Victor Chang Cardiac Research Institute Scientist, Kathryn Wolhuter
Agilent Technologies Inc. (NYSE: A) announced today that the recipient of the 2023 Darlene Solomon Award is Kathryn Wolhuter, Ph.D., a senior postdoctoral researcher studying coronary heart disease
David A. Jones Elected Chairman of the Humana Foundation Board of Directors
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 41 years, today announced that David A. Jones Jr. has been elected to serve as Chairman of the Board of Directors
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2023. The purpose of
Agilent Announced as Instrument Business Outlook 2022 Company of the Year
Agilent Technologies Inc. (NYSE: A) announced today that it has been selected as Instrument Business Outlook (IBO) 2022 Company of the Year. IBO highlighted Agilent's increased growth in revenues
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data support the safety and
Humana Healthy Horizons Invests More Than $1 Million to Help Louisianans Overcome Health Challenges
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), announced today that it has contributed more than $1 million to non-profit
Waters Corporation Listed as No. 5 on Barron's 100 Most Sustainable Companies 2023 List
Waters Corporation’s (NYSE:WAT) companywide commitment to “leaving the world better than we found it” has earned it the number five ranking on the Barron’s 2023 100 Most Sustainable Companies U.S
Pfizer Invests $43 Billion to Battle Cancer
Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology